Bio-Rad Reports Q2 2025 Financial Results
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bio-Rad Laboratories ( (BIO) ) has shared an announcement.
Bio-Rad Laboratories announced its financial results for the second quarter of 2025, reporting a 2.1% increase in total net sales compared to the same period in 2024, driven by higher sales in process chromatography products. The company completed the acquisition of Stilla Technologies, enhancing its Droplet Digital PCR offerings. Despite a slight decline in gross margin and income from operations, Bio-Rad recognized a significant net income due to changes in the fair market value of its investment in Sartorius AG. The company updated its full-year 2025 financial outlook, expecting non-GAAP, currency-neutral revenue growth of approximately 0 to 1.0 percent.
The most recent analyst rating on (BIO) stock is a Buy with a $400.00 price target. To see the full list of analyst forecasts on Bio-Rad Laboratories stock, see the BIO Stock Forecast page.
Spark’s Take on BIO Stock
According to Spark, TipRanks’ AI Analyst, BIO is a Neutral.
Bio-Rad Laboratories’ overall stock score reflects significant financial challenges and a mixed technical outlook. The company’s strategic acquisitions and leadership changes provide a positive, albeit cautious, path forward. The negative P/E and absence of dividends weigh on its valuation, while macroeconomic factors and declining revenue remain key concerns.
To see Spark’s full report on BIO stock, click here.
More about Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. is a global leader in life science research and clinical diagnostics products.
Average Trading Volume: 354,402
Technical Sentiment Signal: Sell
Current Market Cap: $6.88B
Learn more about BIO stock on TipRanks’ Stock Analysis page.
